Improving Skills in Pediatric ALL: Focus on Asparaginase - prIME Oncology
prIME Case
prIME Case

Improving Skills in Pediatric ALL: Focus on Asparaginase

A Case-Based Educational Series: Case Three of Three

Not a member of My prIME? Join now for instant access.

Virtual acute lymphoblastic leukemia (ALL) eCases illustrate best practices for asparaginase treatment management through the use of concise, interactive clinical scenarios. Cases cover different challenges associated with asparaginase use in pediatric and adolescent/young adult (AYA) patients, and present experts’ recommendations along with data to support decision points throughout the patient’s disease course.

Interactive Presentation

Interactive Presentation

CME

CME

0.5 AMA PRA Category 1 Credit

Release Date

Release Date

Sep 12, 2018

Expiration Date

Sep 12, 2019

Your patient is a 4-year-old boy with an unremarkable medical history who presented to his pediatrician for two weeks of fevers, increased bruising, and fatigue. After pallor is noted on physical examination, a complete blood count is drawn, which reveals a white blood cell count of 8 x 109/L, hemoglobin of 5.9 g/dL, and platelets of 26 x 109/L, with 12% peripheral blasts. He is transported to the local pediatric emergency department, where he is started on intravenous (IV) fluids and allopurinol, and frequent laboratory monitoring is implemented to assess for tumor lysis syndrome.

  • Patrick Brown, MDJohns Hopkins University School of Medicine
    Baltimore, Maryland, United States
  • Stacy Cooper, MDJohns Hopkins University School of Medicine
    Baltimore, Maryland, United States

This activity is designed to meet the educational needs of hematologists, pediatric hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with hematologic malignancies.

After successful completion of this educational , participants should be able to:

  • Discuss the use of asparaginase in the treatment of pediatric patients with ALL
  • Develop optimal strategies to manage adverse events related to the use of asparaginase in ALL, including hypersensitivity reactions

This educational activity is supported by a grant from Shire.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Brown has disclosed that he has received consulting fees from Jazz Pharmaceuticals and Shire. He disclosed membership on an advisory committee or review panel for Amgen. He has to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cooper has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.